MKI67 and breast carcinoma: Breast Cancer International Research Group (BCIRG) 001 trial subgroup analysis showed that Ki67 IHC results, whose cutoff value was 14%, can define which ER+/HER2- tumors can get more benefit from adjuvant docetaxel treatment [19].